Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 8/2011

01.08.2011 | Original Article

Prognostic Impact of Preoperative the Branched-Chain Amino Acid to the Tyrosine Ratio in Hepatocellular Carcinoma Patients after Initial Hepatectomy

verfasst von: Toru Mizuguchi, Masaki Kawamoto, Makoto Meguro, Yukio Nakamura, Kohei Harada, Kazuharu Kukita, Koichi Hirata

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 8/2011

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The branched-chain amino acid/tyrosine ratio (BTR) reflects the amino acid balance and the severity of liver disease. The aim of the present study was to determine the relationship between BTR and liver function in patients with hepatocellular carcinoma (HCC). Furthermore, we evaluated the clinical usefulness of BTR as a prognostic indicator of disease-free and overall patient survival after initial hepatectomy.

Methods

Between January 2004 and December 2008, 105 consecutive HCC patients who underwent initial hepatectomy were enrolled in this study. The correlation between BTR and preoperative liver functional indicators was evaluated. The cutoff levels of BTR for 2-year survival prediction were evaluated using a dot blot diagram. The patients were divided into high BTR (4.5 or higher) and low BTR (4.4 or lower) groups and these were compared in terms of clinical variables such as liver functional indicators, operative variables, and tumor characteristics.

Results

The preoperative BTR level decreased according to the severity of liver disease. BTR was correlated with the albumin, bilirubin, and prealbumin levels, as well as the prothrombin time. Although the preoperative liver function was significantly different between the high BTR and low BTR groups, the operative variables and tumor-related variables were not found to be significantly different. Postoperative complications in the high BTR group were significantly less frequent than in the low BTR group (p = 0.003). Disease-free and overall patient survival in the high BTR group were significantly longer than in the low BTR group (p < 0.001 and p = 0.021, respectively).

Conclusions

BTR reflected the pathological liver background with a high correlation to the other liver functional indicators. BTR is thus considered to be a useful marker to predict postoperative complications, disease-free survival, and overall survival of HCC patients after initial hepatectomy. It is, therefore, a useful indicator of liver function and a predictor for the risk of cancer recurrence and overall survival in HCC patients.
Literatur
1.
Zurück zum Zitat El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745–750.PubMedCrossRef El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745–750.PubMedCrossRef
2.
3.
Zurück zum Zitat Schutte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma—epidemiological trends and risk factors. Dig Dis 2009;27:80–92.PubMed Schutte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma—epidemiological trends and risk factors. Dig Dis 2009;27:80–92.PubMed
4.
Zurück zum Zitat Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127:S35-S50.PubMedCrossRef Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127:S35-S50.PubMedCrossRef
5.
Zurück zum Zitat Garcia-Tsao G, Lim JK. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol 2009;104:1802–1829.PubMedCrossRef Garcia-Tsao G, Lim JK. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol 2009;104:1802–1829.PubMedCrossRef
6.
Zurück zum Zitat Poon RT, Fan ST, Ng IO, Wong J. Significance of resection margin in hepatectomy for hepatocellular carcinoma: A critical reappraisal. Ann Surg 2000;231:544–551.PubMedCrossRef Poon RT, Fan ST, Ng IO, Wong J. Significance of resection margin in hepatectomy for hepatocellular carcinoma: A critical reappraisal. Ann Surg 2000;231:544–551.PubMedCrossRef
7.
Zurück zum Zitat Charlton M. Branched-chain amino acid enriched supplements as therapy for liver disease. J Nutr 2006;136:295S–298S.PubMed Charlton M. Branched-chain amino acid enriched supplements as therapy for liver disease. J Nutr 2006;136:295S–298S.PubMed
8.
Zurück zum Zitat Tom A, Nair KS. Assessment of branched-chain amino acid status and potential for biomarkers. J Nutr 2006;136:324S–330S.PubMed Tom A, Nair KS. Assessment of branched-chain amino acid status and potential for biomarkers. J Nutr 2006;136:324S–330S.PubMed
9.
Zurück zum Zitat Fischer JE, Rosen HM, Ebeid AM, James JH, Keane JM, Soeters PB. The effect of normalization of plasma amino acids on hepatic encephalopathy in man. Surgery 1976;80:77–91.PubMed Fischer JE, Rosen HM, Ebeid AM, James JH, Keane JM, Soeters PB. The effect of normalization of plasma amino acids on hepatic encephalopathy in man. Surgery 1976;80:77–91.PubMed
10.
Zurück zum Zitat Moriwaki H, Miwa Y, Tajika M, Kato M, Fukushima H, Shiraki M. Branched-chain amino acids as a protein- and energy-source in liver cirrhosis. Biochem Biophys Res Commun 2004;313:405–409.PubMedCrossRef Moriwaki H, Miwa Y, Tajika M, Kato M, Fukushima H, Shiraki M. Branched-chain amino acids as a protein- and energy-source in liver cirrhosis. Biochem Biophys Res Commun 2004;313:405–409.PubMedCrossRef
11.
Zurück zum Zitat Kvittingen EA. Hereditary tyrosinemia type I—an overview. Scand J Clin Lab Invest Suppl 1986;184:27–34.PubMed Kvittingen EA. Hereditary tyrosinemia type I—an overview. Scand J Clin Lab Invest Suppl 1986;184:27–34.PubMed
12.
Zurück zum Zitat Tanguay RM, Jorquera R, Poudrier J, St-Louis M. Tyrosine and its catabolites: from disease to cancer. Acta Biochim Pol 1996;43:209–216.PubMed Tanguay RM, Jorquera R, Poudrier J, St-Louis M. Tyrosine and its catabolites: from disease to cancer. Acta Biochim Pol 1996;43:209–216.PubMed
13.
Zurück zum Zitat Fulenwider JT, Nordlinger BM, Faraj BA, Ivey GL, Rudman D. Deranged tyrosine metabolism in cirrhosis. Yale J Biol Med 1978;51:625–633.PubMed Fulenwider JT, Nordlinger BM, Faraj BA, Ivey GL, Rudman D. Deranged tyrosine metabolism in cirrhosis. Yale J Biol Med 1978;51:625–633.PubMed
14.
Zurück zum Zitat Azuma Y, Maekawa M, Kuwabara Y, Nakajima T, Taniguchi K, Kanno T. Determination of branched-chain amino acids and tyrosine in serum of patients with various hepatic diseases, and its clinical usefulness. Clin Chem 1989;35:1399–1403.PubMed Azuma Y, Maekawa M, Kuwabara Y, Nakajima T, Taniguchi K, Kanno T. Determination of branched-chain amino acids and tyrosine in serum of patients with various hepatic diseases, and its clinical usefulness. Clin Chem 1989;35:1399–1403.PubMed
15.
Zurück zum Zitat Suzuki K, Koizumi K, Ichimura H, Oka S, Takada H, Kuwayama H. Measurement of serum branched-chain amino acids to tyrosine ratio level is useful in a prediction of a change of serum albumin level in chronic liver disease. Hepatol Res 2008;38:267–272.PubMedCrossRef Suzuki K, Koizumi K, Ichimura H, Oka S, Takada H, Kuwayama H. Measurement of serum branched-chain amino acids to tyrosine ratio level is useful in a prediction of a change of serum albumin level in chronic liver disease. Hepatol Res 2008;38:267–272.PubMedCrossRef
16.
Zurück zum Zitat Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205–213.PubMedCrossRef Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205–213.PubMedCrossRef
17.
Zurück zum Zitat Ninomiya T, Yoon S, Sugano M, Kumon Y, Seo Y, Shimizu K, Nagano H, Kasuga M, Hayashi Y. Improvement of molar ratio of branched-chain amino acids to tyrosine (BTR) associated with liver fibrosis in chronic hepatitis C patients treated with interferon-alpha. Dig Dis Sci 1999;44:1027–1033.PubMedCrossRef Ninomiya T, Yoon S, Sugano M, Kumon Y, Seo Y, Shimizu K, Nagano H, Kasuga M, Hayashi Y. Improvement of molar ratio of branched-chain amino acids to tyrosine (BTR) associated with liver fibrosis in chronic hepatitis C patients treated with interferon-alpha. Dig Dis Sci 1999;44:1027–1033.PubMedCrossRef
18.
Zurück zum Zitat Kohashi T, Itamoto T, Katayama K, Katayama S, Hino H, Nakahara H, Tashiro H, Asahara T. Significance of the molar ratio of branched-chain amino acids to tyrosine before hepatectomy. Hepatogastroenterology 2002;49:774–777.PubMed Kohashi T, Itamoto T, Katayama K, Katayama S, Hino H, Nakahara H, Tashiro H, Asahara T. Significance of the molar ratio of branched-chain amino acids to tyrosine before hepatectomy. Hepatogastroenterology 2002;49:774–777.PubMed
19.
Zurück zum Zitat Kawamura-Yasui N, Kaito M, Nakagawa N, Fujita N, Ikoma J, Gabazza EC, Watanabe S, Adachi Y. Evaluating response to nutritional therapy using the branched-chain amino acid/tyrosine ratio in patients with chronic liver disease. J Clin Lab Anal 1999;13:31–34.PubMedCrossRef Kawamura-Yasui N, Kaito M, Nakagawa N, Fujita N, Ikoma J, Gabazza EC, Watanabe S, Adachi Y. Evaluating response to nutritional therapy using the branched-chain amino acid/tyrosine ratio in patients with chronic liver disease. J Clin Lab Anal 1999;13:31–34.PubMedCrossRef
20.
21.
Zurück zum Zitat Tjoeng MM, Bartelink AK, Thijs LG. Exploding the albumin myth. Pharm World Sci 1999;21:17–20.PubMedCrossRef Tjoeng MM, Bartelink AK, Thijs LG. Exploding the albumin myth. Pharm World Sci 1999;21:17–20.PubMedCrossRef
22.
Zurück zum Zitat Rondana M, Milani L, Merkel C, Caregaro L, Gatta A. Value of prealbumin plasma levels as liver test. Digestion 1987;37:72–78.PubMedCrossRef Rondana M, Milani L, Merkel C, Caregaro L, Gatta A. Value of prealbumin plasma levels as liver test. Digestion 1987;37:72–78.PubMedCrossRef
23.
Zurück zum Zitat Spiekerman AM. Nutritional assessment (protein nutriture). Anal Chem 199;67:429R–436R. Spiekerman AM. Nutritional assessment (protein nutriture). Anal Chem 199;67:429R–436R.
24.
Zurück zum Zitat Beck FK, Rosenthal TC. Prealbumin: a marker for nutritional evaluation. Am Fam Physician 2002;65:1575–1578.PubMed Beck FK, Rosenthal TC. Prealbumin: a marker for nutritional evaluation. Am Fam Physician 2002;65:1575–1578.PubMed
25.
Zurück zum Zitat Yanaga K. Current status of hepatic resection for hepatocellular carcinoma. J Gastroenterol 2004;39:919–926.PubMedCrossRef Yanaga K. Current status of hepatic resection for hepatocellular carcinoma. J Gastroenterol 2004;39:919–926.PubMedCrossRef
26.
Zurück zum Zitat Mizuguchi T, Katsuramaki T, Nobuoka T, Kawamoto M, Oshima H, Kawasaki H, Kikuchi H, Shibata C, Hirata K. Serum hyaluronate level for predicting subclinical liver dysfunction after hepatectomy. World J Surg 2004;28:971–976.PubMedCrossRef Mizuguchi T, Katsuramaki T, Nobuoka T, Kawamoto M, Oshima H, Kawasaki H, Kikuchi H, Shibata C, Hirata K. Serum hyaluronate level for predicting subclinical liver dysfunction after hepatectomy. World J Surg 2004;28:971–976.PubMedCrossRef
27.
Zurück zum Zitat Kaibori M, Ishizaki M, Saito T, Matsui K, Kwon AH, Kamiyama Y. Risk factors and outcome of early recurrence after resection of small hepatocellular carcinomas. Am J Surg 2009;198:39–45.PubMedCrossRef Kaibori M, Ishizaki M, Saito T, Matsui K, Kwon AH, Kamiyama Y. Risk factors and outcome of early recurrence after resection of small hepatocellular carcinomas. Am J Surg 2009;198:39–45.PubMedCrossRef
28.
Zurück zum Zitat Ruzzenente A, Capra F, Pachera S, Iacono C, Piccirillo G, Lunardi M, Pistoso S, Valdegamberi A, D'Onofrio M, Guglielmi A. Is liver resection justified in advanced hepatocellular carcinoma? Results of an observational study in 464 patients. J Gastrointest Surg 2009;13:1313–1320.PubMedCrossRef Ruzzenente A, Capra F, Pachera S, Iacono C, Piccirillo G, Lunardi M, Pistoso S, Valdegamberi A, D'Onofrio M, Guglielmi A. Is liver resection justified in advanced hepatocellular carcinoma? Results of an observational study in 464 patients. J Gastrointest Surg 2009;13:1313–1320.PubMedCrossRef
29.
Zurück zum Zitat Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int 2009;29:502–510.PubMedCrossRef Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int 2009;29:502–510.PubMedCrossRef
30.
Zurück zum Zitat Yasui M, Harada A, Torii A, Nakao A, Nonami T, Takagi H. Impaired liver function and long-term prognosis after hepatectomy for hepatocellular carcinoma. World J Surg 1995;19:439–443.PubMedCrossRef Yasui M, Harada A, Torii A, Nakao A, Nonami T, Takagi H. Impaired liver function and long-term prognosis after hepatectomy for hepatocellular carcinoma. World J Surg 1995;19:439–443.PubMedCrossRef
31.
Zurück zum Zitat Mizuguchi T, Nagayama M, Meguro M, Shibata T, Kaji S, Nobuoka T, Kimura Y, Furuhata T, Hirata K. Prognostic impact of surgical complications and preoperative serum hepatocyte growth factor in hepatocellular carcinoma patients after initial hepatectomy. J Gastrointest Surg 2009;13:325–333.PubMedCrossRef Mizuguchi T, Nagayama M, Meguro M, Shibata T, Kaji S, Nobuoka T, Kimura Y, Furuhata T, Hirata K. Prognostic impact of surgical complications and preoperative serum hepatocyte growth factor in hepatocellular carcinoma patients after initial hepatectomy. J Gastrointest Surg 2009;13:325–333.PubMedCrossRef
32.
Zurück zum Zitat Marchesini G, Dioguardi FS, Bianchi GP, Zoli M, Bellati G, Roffi L, Martines D, Abbiati R. Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy. A randomized double-blind casein-controlled trial. The Italian Multicenter Study Group. J Hepatol 1990;11:92–101.PubMedCrossRef Marchesini G, Dioguardi FS, Bianchi GP, Zoli M, Bellati G, Roffi L, Martines D, Abbiati R. Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy. A randomized double-blind casein-controlled trial. The Italian Multicenter Study Group. J Hepatol 1990;11:92–101.PubMedCrossRef
33.
Zurück zum Zitat Fan ST, Lo CM, Lai EC, Chu KM, Liu CL, Wong J. Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma. N Engl J Med 1994;331:1547–1552.PubMedCrossRef Fan ST, Lo CM, Lai EC, Chu KM, Liu CL, Wong J. Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma. N Engl J Med 1994;331:1547–1552.PubMedCrossRef
34.
Zurück zum Zitat Long-term oral administration of branched chain amino acids after curative resection of hepatocellular carcinoma: a prospective randomized trial. The San-in Group of Liver Surgery. Br J Surg 1997;84:1525–1531. Long-term oral administration of branched chain amino acids after curative resection of hepatocellular carcinoma: a prospective randomized trial. The San-in Group of Liver Surgery. Br J Surg 1997;84:1525–1531.
35.
Zurück zum Zitat Marchesini G, Bianchi G, Merli M, Amodio P, Panella C, Loguercio C, Rossi Fanelli F, Abbiati R. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology 2003;124:1792–1801.PubMedCrossRef Marchesini G, Bianchi G, Merli M, Amodio P, Panella C, Loguercio C, Rossi Fanelli F, Abbiati R. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology 2003;124:1792–1801.PubMedCrossRef
Metadaten
Titel
Prognostic Impact of Preoperative the Branched-Chain Amino Acid to the Tyrosine Ratio in Hepatocellular Carcinoma Patients after Initial Hepatectomy
verfasst von
Toru Mizuguchi
Masaki Kawamoto
Makoto Meguro
Yukio Nakamura
Kohei Harada
Kazuharu Kukita
Koichi Hirata
Publikationsdatum
01.08.2011
Verlag
Springer-Verlag
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 8/2011
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-011-1566-y

Weitere Artikel der Ausgabe 8/2011

Journal of Gastrointestinal Surgery 8/2011 Zur Ausgabe

SSAT/SAGES Joint Symposium

TEM as a Platform for NOTES

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Deutlich weniger Infektionen: Wundprotektoren schützen!

08.05.2024 Postoperative Wundinfektion Nachrichten

Der Einsatz von Wundprotektoren bei offenen Eingriffen am unteren Gastrointestinaltrakt schützt vor Infektionen im Op.-Gebiet – und dient darüber hinaus der besseren Sicht. Das bestätigt mit großer Robustheit eine randomisierte Studie im Fachblatt JAMA Surgery.

Chirurginnen und Chirurgen sind stark suizidgefährdet

07.05.2024 Suizid Nachrichten

Der belastende Arbeitsalltag wirkt sich negativ auf die psychische Gesundheit der Angehörigen ärztlicher Berufsgruppen aus. Chirurginnen und Chirurgen bilden da keine Ausnahme, im Gegenteil.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.